HylaPharm is a university spinout company developing new targeted cancer therapies. HylaPlat is a new cancer drug that has already shown efficacy. It is the first targeted chemotherapy for potentially deadly, locally advanced cancers that affect nearly 200,000 Americans.HylaPlat is injected directly into the primary tumor, resulting in very high tumor penetration. HylaPlat is manufactured in university incubator space and is a novel complex of already approved drugs. Kansas BioScience Authority has funded upcoming FDA Investigational New Drug-enabling animal trials. The Kansas Department of Commerce has qualified HylaPharm as a Kansas Angel company.
